This Article Full Text Full Text (PDF) CME: Take the course for this article: Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eckardt, J. R. Search for Related Content PubMed PubMed Citation Articles by Eckardt, J. R.

Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer

The Center for Cancer Care and Research, St. Louis, Missouri, USA

Correspondence: John R. Eckardt, M.D., The Center for Cancer Care and Research, 12855 North Forty Drive, Suite 200, St. Louis, Missouri 63141, USA. Telephone: 314-628-1210; Fax: 314-628-1220; e-mail: jeckardt{at}tcccr.com

Small cell lung cancer (SCLC) is an aggressive tumor that often metastasizes before the primary cancer is diagnosed. Patients with SCLC are typically elderly and often have comorbidities that may predispose them to adverse events during therapy. Although topotecan (Hycamtin^®; GlaxoSmithKline; Philadelphia, PA), 1.5 mg/m²/day via a 30-minute i.v. infusion on days 1–5 of a 21-day cycle, is a standard therapy for relapsed SCLC, this regimen can result in significant neutropenia, especially in previously treated patients. This hematologic toxicity is noncumulative and reversible, but its management can be challenging in this poor-prognosis population. Therefore, alternate treatment regimens have been investigated. Weekly topotecan (4.0 mg/m²) is currently investigational and has shown promising activity and favorable tolerability in patients with relapsed ovarian cancer, another aggressive malignancy with a poor prognosis. Preliminary results from a phase II trial of weekly bolus topotecan (4.0 mg/m²) in patients with recurrent SCLC were recently reported, and this regimen was generally well tolerated. Furthermore, weekly topotecan has been successfully included in several combination therapy regimens in patients with a variety of solid tumors. In untreated SCLC patients, a combination regimen of weekly topotecan, paclitaxel (Taxol^®; Bristol-Myers Squibb; Princeton, NJ), and cisplatin (Platinol^®; Bristol-Myers Squibb) was explored and found to be well tolerated and active in patients with extensive and limited-stage disease. Further clinical trials of weekly topotecan and regimens that include weekly topotecan in the SCLC setting are warranted.

Key Words. Alternate schedule • Recurrent • Small cell lung cancer • Topotecan • Weekly topotecan

This article has been cited by other articles:

				S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J.-H. Lee, et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., February 1, 2006; 12(3): 878 - 887. [Abstract] [Full Text] [PDF]